Filing Details

Accession Number:
0001179110-18-010499
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-08-10 16:31:12
Reporting Period:
2018-08-08
Accepted Time:
2018-08-10 16:31:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235010 Momenta Pharmaceuticals Inc MNTA Biological Products, (No Disgnostic Substances) (2836) 043561634
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1345695 Bruce Leicher C/O Momenta Pharmaceuticals, Inc.
301 Binney Street
Cambridge MA 02142
Svp & General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-08-08 1,346 $0.00 172,869 No 4 M Direct
Common Stock Disposition 2018-08-08 400 $29.00 172,469 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2018-08-08 1,346 $0.00 1,346 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
13,453 No 4 M Direct
Footnotes
  1. Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017.
  2. Includes 476 shares acquired under the issuer's employee stock purchase plan at a purchase price of $14.20 per share on July 31, 2018.
  3. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  4. Restricted Stock Units convert into common stock on a one-for-one basis.
  5. Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.